Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
epidermal growth factor receptor (EGFR)
Biotech
Hoth strikes back against skin toxicities but stock stays frozen
Hoth shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another milestone for the candidate.
Nick Paul Taylor
Jan 22, 2026 10:38am
J&J, Google venture arms line up to back EpiBiologics' series B
Jan 8, 2026 9:05am
Cullinan plans approval push for NSCLC drug after ph. 2 win
Jan 29, 2025 6:15am
Avenue secure rare disease med while Allist lands cancer drug
Mar 2, 2023 11:00am
